T. Rowe Price Associates, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing its beneficial ownership position in Kodiak Sciences Inc. as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 2,934,560 shares of Kodiak Sciences Inc. common stock.
- Percent of class: The reported position represents 4.7% of the outstanding class of common stock.
- Sole voting power: T. Rowe Price holds sole voting power over 2,930,763 shares, with no shared voting power reported.
- Sole dispositive power: The filing attributes sole dispositive power over 2,934,560 shares to T. Rowe Price, with no shared dispositive power.
- Event date: The date of the event requiring the filing is stated as September 30, 2026.
- Filer classification: T. Rowe Price Associates, Inc. is identified as an investment adviser (type "IA"), organized in Maryland.
T. Rowe Price's Amended Ownership Disclosure for Kodiak Sciences Common Stock
T. Rowe Price Associates, Inc., a Maryland-incorporated investment adviser headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 1 to its Schedule 13G regarding its holdings in Kodiak Sciences Inc. (NASDAQ:KOD). According to the filing, the event triggering the amendment occurred on September 30, 2026, and the statement was signed by Ellen York, Vice President, on November 16, 2026.
The filing discloses that T. Rowe Price beneficially owns 2,934,560 shares of Kodiak Sciences common stock (CUSIP 50015M109), representing 4.7% of the class. Of those shares, 2,930,763 are subject to sole voting power and 2,934,560 are subject to sole dispositive power. The filing reports zero shared voting power and zero shared dispositive power. Item 5 of the filing notes ownership of 5 percent or less of the class.
The filing includes a certification stating that, to the best of the filer's knowledge, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also includes a declaration that "the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied." Kodiak Sciences Inc. is listed as having its principal executive offices at 1250 Page Mill Rd, Palo Alto, CA 94304.
What Was Disclosed
T. Rowe Price Associates, Inc. filed Amendment No. 1 to Schedule 13G disclosing beneficial ownership of 2,934,560 shares, or 4.7%, of Kodiak Sciences Inc. common stock as of September 30, 2026, with sole voting power over 2,930,763 shares and sole dispositive power over all 2,934,560 shares.



Please wait processing your request...